Electroacupuncture Reduces Fibromyalgia Pain by Attenuating the HMGB1, S100B, and TRPV1 Signalling Pathways in the Mouse Brain.

Fibromyalgia causes widespread chronic pain and muscle tenderness that can be difficult to treat with conventional medicine. Researchers studied whether electroacupuncture (EA) could relieve fibromyalgia-like pain in mice and discovered how it works in the brain. Scientists created fibromyalgia symptoms in mice using repeated cold stress, which made them extremely sensitive to both touch and temperature. They then treated some mice with electroacupuncture at the ST36 point (located on the lower leg) for 20 minutes daily over three days, using mild electrical stimulation at 2 Hz frequency. The results were significant: mice receiving electroacupuncture showed major improvements in pain sensitivity. Their mechanical pain threshold increased from 1.43g to 4.62g, and their heat tolerance improved from 3.98 seconds to 7.68 seconds. Brain analysis revealed that electroacupuncture worked by reducing activity in specific pain-signaling pathways (HMGB1, S100B, and TRPV1) in four key brain regions: the prefrontal cortex, somatosensory cortex, thalamus, and amygdala. Interestingly, mice genetically modified to lack the TRPV1 receptor showed similar pain relief, suggesting this receptor is a crucial target. This study provides scientific evidence that electroacupuncture may help fibromyalgia patients by calming overactive pain signals in the central nervous system rather than just treating symptoms at the pain site. While this research was conducted in mice, it offers promising insights into why acupuncture helps some fibromyalgia patients and identifies specific biological mechanisms involved. If you're considering electroacupuncture for fibromyalgia, consult with a licensed acupuncturist trained in this specialized technique.

This murine study investigated electroacupuncture's therapeutic mechanisms in fibromyalgia-like pain induced by intermittent cold stress. EA parameters: 2 Hz, 1 mA, 20 minutes at ST36, administered days 3-5. Results demonstrated significant reversal of both mechanical hyperalgesia (1.43±0.34g to 4.62±0.48g) and thermal hyperalgesia (3.98±0.73s to 7.68±0.68s). Mechanistic analysis revealed EA attenuated upregulated HMGB1, S100B, and TRPV1 signaling pathways in prefrontal cortex, somatosensory cortex, thalamus, and amygdala. Trpv1-/- mice demonstrated comparable analgesic effects (mechanical: 4.38±0.51g; thermal: 7.48±0.98s), confirming TRPV1-dependent mechanisms. Clinical implications: This evidence supports EA's central neuromodulatory effects in fibromyalgia pain management, specifically targeting neuroinflammatory and nociceptive pathways. The TRPV1 pathway represents a potential biomarker for identifying EA-responsive fibromyalgia phenotypes. Low-frequency (2 Hz) EA at ST36 appears sufficient for central sensitization modulation, offering a standardized treatment protocol for clinical application in fibromyalgia management.